Thus, the classification scheme showed prognostic value independent of tumor grade, IDH1/2 status, patient age and therapies (not independent of IDH1 status, age, MGMT promoter methylation and therapies in TCGA GBM samples). The gene discussed is MGMT; the disease is neoplasm.